TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22819803
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg taurine
Study: 22819803
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine + 50 g glucose
Study: 22819803
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg taurine + 50 g glucose
Study: 17493196
Drug: ALN 70
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 70 mg once a week plus calcitriol (1,25D3) 0.5 microg daily
Study: 17493196
Drug: ALN 70
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 70 mg once a week alone
Study: 9609267
Drug: Oestradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (2 mg daily) for 20 to 24 weeks
Study: 7639104
Drug: Transcutaneous 17‐beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous 17‐beta‐estradiol (50 micrograms daily)
Study: 7639104
Drug: Cyclical intravenous
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical intravenous clodronate (200 mg/month iv infusion)
Study: 2560289
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (duration: 6 months)
Study: 2560289
Drug: Normotensive controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normotensive controls (no treatment)
Study: 791563
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) at doses of 0, 150, or 500 mug/kg
Study: 791563
Drug: Secobarbital (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (150 mg/70 kg)
Study: 791563
Drug: Secobarbital (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (150 mg/70 kg) with CBD pretreatment
Study: 23438937
Drug: Mirtazapine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (45 mg daily)
Study: 20638340
Drug: Atosiban (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (37.5 mg intravenous administration before embryo transfer)
Study: 11926622
Drug: Daily PEFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PEFR monitoring
Study: 455950
Drug: Nonscheduled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonscheduled therapy
Study: 29044000
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection combined with Cefoxitin Sodium
Study: 23798006
Drug: Androgen suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen suppression therapy (AST) for 6 months
Study: 22772617
Drug: Nano-emulsion gel
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-emulsion gel formulation of adapalene 0.1% and clindamycin 1%
Study: 22772617
Drug: Conventional gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gel formulation of adapalene 0.1% and clindamycin 1%
Study: 19740402
Drug: BX471 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BX471 at therapeutic doses
Study: 15372178
Drug: Biken two-component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biken two-component (23.4 mg PT; 23.4 mg FHA) Pa vaccine (0.5 ml)
Study: 3986084
Drug: Amitriptyline hydrochloride
Normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride (50 mg or 100 mg)
Study: 3986084
Drug: Binodaline hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binodaline hydrochloride (50 mg or 100 mg)
Study: 30803706
Drug: Spironolactone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (maximum dose, 50mg/d) for 24 weeks
Study: 25140597
Drug: Supplement with
Normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement with ω6:ω3 ratio of 8:1 and arginine
Study: 25140597
Drug: Supplement with
Normalized name: NESTABS DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement with high ω9:ω6 ratio of 3.2:1 and low ω6:ω3 ratio of 1.4:1 and arginine
Study: 19306038
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/day)
Study: 17724802
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/d
Study: 17724802
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg/d
Study: 18035206
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg/d
Study: 11740701
Drug: Clarithromycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (15 mg/kg/day in 2 divided doses for 7 days)
Study: 11740701
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/day in 1 dose for 3 days)
Study: 19259717
Drug: ANN-guided CPAP
Normalized name: trastuzumab-anns
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ANN-guided CPAP titration
Study: 22253054
Drug: Conventional CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CPAP titration
Study: 15229100
Drug: Fluticasone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (500 mcg twice a day)
Study: 15229100
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (30 mg/day)
Study: 15229100
Drug: Fluticasone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (500 mcg twice a day for an additional 8 weeks)
Study: 11395591
Drug: Diltiazem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (25 mg bolus followed by 20 mg/hr continuous infusion for 24 hrs)
Study: 11395591
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg bolus)
Study: 11395591
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg bolus followed by 45 mg/hr for 24 hrs)
Study: 9244941
Drug: Propofol (0.8‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.8‐1 mg/kg for induction; 4‐6 mg/kg/h for maintenance)
Study: 9244941
Drug: Etomidate (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.25 mg/kg for induction) and isoflurane (0.6‐0.8% for maintenance)
Study: 26293443
Drug: BUP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP at a dose of 150mg/day for 3 days, subsequently increased to 300mg/day
Study: 26293443
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum of 4mg every 1-2 hourly for initial 6 weeks, then every 2-4 hourly for next 6 weeks
Study: 26293443
Drug: Behavioral Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral Intervention (BI) + Nicotine Replacement Therapy (NRT)
Study: 23834653
Drug: Sivelestat (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.2 mg/kg/h continuous intravenous infusion)
Study: 16960287
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin 7.0 g/dL maintained between 7.0 and 9.0 g/dL)
Study: 16960287
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin 10.0 g/dL maintained between 10.0 and 12.0 g/dL)
Study: 8106653
Drug: Paroxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10 to 50 mg/day)
Study: 3539709
Drug: Intravenous branched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous branched chain amino acids in 20% dextrose (group A)
Study: 3539709
Drug: Oral lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral lactulose (group B)
Study: 3539709
Drug: Intravenous branched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous branched chain amino acids (preliminary uncontrolled study)
Study: 14587302
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose triple therapy (omeprazole, amoxicillin, clarithromycin) for 1 week
Study: 14587302
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose triple therapy (omeprazole, amoxicillin, clarithromycin) for 1 week
Study: 14587302
Drug: Failed eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Failed eradication therapy
Study: 7529038
Drug: Aprotinin (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high-dose regimen)
Study: 19651344
Drug: Analgesics taken
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics taken
Study: 19651344
Drug: No analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesics taken
Study: 17804348
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support intervention for promoting antiretroviral therapy adherence
Study: 14987268
Drug: 6 treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 treatments of psoralen‐UVA (PUVA) therapy
Study: 14987268
Drug: 12 treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 treatments of psoralen‐UVA (PUVA) therapy
Study: 9551739
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules plus canola oil and margarine (omega‐3 group)
Study: 9551739
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil capsules plus sunflower oil and margarine (omega‐6 group)
Study: 7998418
Drug: TGP-943 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGP-943 vaccine
Study: 3045202
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g/day) for 8 weeks
Study: 3045202
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g/day) for 8 weeks followed by 1,25-(OH)2 vitamin D3 (0.5 micrograms/day) for 2 weeks
Study: 25817323
Drug: Therapist-supervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-supervised therapy provided by a certified hand therapist (CHT)
Study: 21228246
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin regimen (glargine once daily and glulisine before meals)
Study: 21228246
Drug: Sliding scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale regular insulin (SSI) four times daily
Study: 23435159
Drug: Sliding scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale regular insulin (SSI)
Study: 18820311
Drug: Blind intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind intra-articular injections (IAIs) in peripheral joints
Study: 16801461
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) in patients with new-onset AF
Study: 11035135
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 (300 mg once daily)
Study: 9385122
Drug: Raloxifene (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (all doses)
Study: 1539846
Drug: PCA supplemented
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA supplemented with a nighttime infusion of morphine 1.0 mg.h-1
Study: 30895697
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily in addition to standard care
Study: 27325392
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) + Contingency Management (CM)
Study: 27325392
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) alone
Study: 25035081
Drug: Fludrocortisone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.4 mg)
Study: 19527368
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for osteolymphoma (chemotherapy and radiotherapy)
Study: 16430566
Drug: Target controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled propofol 3 microg.ml(‐1) infusion
Study: 9377859
Drug: Propranolol at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol at a dose of 240 mg/day for 30 days
Study: 1543450
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% indomethacin aqueous suspension
Study: 23419093
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride solution)
Study: 8646143
Drug: Active cream
Normalized name: NIACINAMIDE 2 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL CREAM [INCELLDERM ACTIVE CREAMEX]
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active cream
Study: 27433837
Drug: D-002 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-002 (50 mg/d)
Study: 27433837
Drug: D-003 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-003 (10 mg/d)
Study: 27433837
Drug: D-002/D-003 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-002/D-003 (50 mg/d of D-002 plus 10 mg/d of D-003)
Study: 22998742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of buspirone 15 mg and melatonin-SR 3 mg
Study: 22998742
Drug: Buspirone 15
Normalized name: busPIRone 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 15 mg monotherapy
Study: 20648928
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron as FCM given as an i.v. bolus injection
Study: 20648928
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg iron as FCM given as an i.v. infusion over 15 min
Study: 20648928
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg iron as FCM given as an i.v. infusion over 15 min
Study: 20648928
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg iron as FCM given as an i.v. infusion over 15 min
Study: 15819586
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel for 12 months after PCI with DES
Study: 15819586
Drug: Clopidogrel for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel for 4 weeks plus aspirin after PCI with DES
Study: 15819586
Drug: Combined antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antithrombotic therapy with aspirin and clopidogrel
Study: 9005786
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ofloxacin 400 mg once a day (group I)
Study: 9005786
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of ofloxacin 200 mg twice a day for 2 to 4 days followed by oral use of 400 mg once a day for 6 to 8 days (group II)
Study: 1930700
Drug: Herbal ingredients
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal ingredients in toothpaste and oral rinse
Study: 773413
Drug: Placebo preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparations
Study: 7074749
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate (average daily dose 436 mg)
Study: 7074749
Drug: Flecainide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide therapy
Study: 7074749
Drug: Flecainide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide therapy after 1 week
Study: 7074749
Drug: Flecainide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide therapy after 2 weeks
Study: 7074749
Drug: Flecainide concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide concentrations of 200‐800 ng/ml
Study: 31291207
Drug: cCBT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: cCBT program 'Good Days Ahead' with weekly guidance and support
Study: 12653894
Drug: Phenobarbital (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (150 mg) for 7 days
Study: 12653894
Drug: Phenobarbital (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (150 mg) for 7 days in subgroup IB (n = 22)
Study: 10591823
Drug: Ondansetron orally
Normalized name: Ondansetron Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron orally disintegrating tablet (ondODT) 8 mg
Study: 10591823
Drug: Ondansetron orally
Normalized name: Ondansetron Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron orally disintegrating tablet (ondODT) 16 mg
Study: 8877126
Drug: 15-, 45-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-, 45-, or 135-micrograms doses of monovalent influenza A/Taiwan (H1N1) hemagglutinin (HA) vaccine
Study: 8877126
Drug: 15-, 45-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-, 45-, or 135-micrograms doses of subvirion (SV) vaccine
Study: 6210562
Drug: Mezlocillin 1
Normalized name: mezlocillin 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin 1 g
Study: 6210562
Drug: Mezlocillin 3
Normalized name: mezlocillin 3 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin 3 g
Study: 6210562
Drug: Mezlocillin 5
Normalized name: Mezlocilline
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mezlocillin 5 g
Study: 30694322
Drug: Hydrocortisone (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (cumulative dose, 72.5 mg/kg)
Study: 23701917
Drug: GSK256066 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256066 25 μg
Study: 23701917
Drug: GSK256066 87.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256066 87.5 μg
Study: 16757200
Drug: Stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride gel (control group)
Study: 16757200
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stannous fluoride gel)
Study: 1772463
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg t.i.d. for 24 weeks
Study: 27138789
Drug: 25(OH)D (≥30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D (≥30 ng/mL)
Study: 25132143
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 400 mg oral zinc sulfate with podophyllin
Study: 25132143
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 400 mg oral zinc sulfate with imiquimod
Study: 25132143
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 400 mg oral zinc sulfate with cryotherapy
Study: 22035976
Drug: Collagen/thrombin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen/thrombin and autologous platelet hemostatic agent (standard hemostasis plus study product)
Study: 12152252
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day p.o. aspirin for 3 days
Study: 12152252
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day p.o. aspirin for 3 days
Study: 30669202
Drug: Clarithromycin 250mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250mg/day + Budesonide nasal spray once a day
Study: 30669202
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray once a day
Study: 25453593
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - 12 daily exposures to vegetable puree added to milk (days 1-12), then 12 x 2 daily exposures to vegetable puree added to rice (days 13-24)
Study: 25453593
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - Plain milk and rice given, followed by 11 daily exposures to vegetable puree
Study: 25453593
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 11 daily exposures to vegetable puree after initial interventions
Study: 19636603
Drug: Watercress extract
Normalized name: watercress allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watercress extract (WCE) 0.1-10 microL/mL
Study: 19636603
Drug: Watercress consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watercress consumption (85 g per day for 8 weeks)
Study: 15497672
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Seralin)